about
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyMinimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendationsPrevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype.High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemiaDiagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblastsRecommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.Long-term follow-up of chronic autoimmune thrombocytopenic purpura refractory to splenectomy: a prospective analysis.A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes.Supportive care including growth factors in myelodysplastic syndromes.[Dysmyelopoeisis].Treatment of the 5q- syndrome.A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome.The role of lenalidomide in the management of myelodysplasia with del 5q.Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemSafety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes.Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.How we treat lower-risk myelodysplastic syndromes.Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes.Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes.Treatment of myelodysplastic syndrome with thrombomimetic drugs.Refractory thrombocytopenia and neutropenia: a diagnostic challenge.Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patients.[Management of myelodysplastic syndromes].Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des MyelodysplasiesLenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies.
P50
Q24563021-29895C03-CA62-4DBE-AE88-96F35E641A72Q26865362-92B1276B-375A-452F-B74E-E577FCDC8193Q27824842-348C2542-E961-4880-A0A8-DAA718D14B76Q27824871-371F4DDF-1DBB-40A0-AC27-C8111CC6E8A2Q27853006-5CF4E0D7-AB2B-4EAC-B8C8-765FC6E4E468Q28066544-D2B55A88-A682-431A-84EA-50B21DCEF4E6Q28236628-60ACB8FE-9852-4881-BA23-3729EAAFFB49Q28296187-1E3C7639-733A-4B76-A493-90E416A8BB18Q30235460-5D73F98F-3FA4-4618-B05B-20E13158297EQ33302879-D1C95E1B-49FA-40B1-9CDF-4A7A907CD8F7Q33347074-85A7622C-72EB-425B-B54B-718C853729A3Q33361012-0090AB73-3E92-4960-8EC9-0CB5AD6ACB5BQ33367365-BC0EFD8E-25FD-4605-826C-DFBF0806EC4CQ33369814-27BF69C6-AB33-4815-BCFA-7E391C80037EQ33373374-1729539C-DD0C-44F2-A294-4F9FDC0F236BQ33374053-608BD367-0F6D-4B6D-A3AA-9AA7C95615DEQ33378398-D6F5540A-29FA-42DA-9894-5D2DFCF8F0FDQ33379527-38298A8F-1BE4-469F-93F6-7C1E635600C7Q33380307-CC07E2C8-B9C7-48C9-9B7A-E9DF5CEFC754Q33387521-7E1BE99F-E96E-47B4-841F-4B1AAC0FD009Q33389465-A0DC2FD0-4489-486F-85FE-51BA5B27AAD0Q33392293-72E47060-43BD-409E-A448-F8C927339456Q33396001-B035FF11-819A-49B2-8FDE-80DE465C34F8Q33398044-90DD62BF-6A8D-41F6-8491-AC82000C3A3DQ33400617-01A0466A-FBD2-41B5-BBE0-91A5738025ADQ33406996-36F562C5-485A-461A-9653-7DFDF41A497CQ33409859-AE1EB483-7127-44D8-9600-21ED03D4F537Q33412937-D8F66C6B-7966-4DD4-8D7D-63D6727E9ADFQ33414453-B87B17AD-C5B9-469F-872B-91BC1744D65FQ33416541-8AC3E86F-FFCB-4A06-81A9-3F490B7E2529Q33419732-C5E5CF69-EDB1-4F72-81FB-3E228924E142Q33420934-48263346-BDD8-41B3-88E4-AF179A8C307FQ33422846-A5DB9193-9C99-4942-BAF3-AE963A9D4216Q33426248-BCC15794-8D1F-41D2-8F38-9B4BB1A0BAB9Q33430655-36A72D02-85B3-4E4F-8B32-CED7FCB619A4Q33433485-BB997709-0F3D-4E2A-B1C1-4F6DE47CEB2EQ33439015-BD03F4B0-F475-4037-B3A3-0D5FE2319430Q33442715-AE5D0018-1272-44EF-BC7C-D1BBDA116DEFQ33518976-07F537E3-AEDB-418C-AF6C-4DE3224014B1Q33574178-5FC7563E-4BFE-4242-8341-04204B07703E
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Pierre Fenaux
@ast
Pierre Fenaux
@en
Pierre Fenaux
@es
Pierre Fenaux
@nl
Pierre Fenaux
@sl
type
label
Pierre Fenaux
@ast
Pierre Fenaux
@en
Pierre Fenaux
@es
Pierre Fenaux
@nl
Pierre Fenaux
@sl
prefLabel
Pierre Fenaux
@ast
Pierre Fenaux
@en
Pierre Fenaux
@es
Pierre Fenaux
@nl
Pierre Fenaux
@sl
P214
P244
P268
P269
P106
P21
P213
0000 0000 0141 138X
P214
P244
no2014075471
P268
P269
P31
P496
0000-0002-0468-3553
P569
1950-01-01T00:00:00Z
P735
P7859
lccn-no2014075471